{"product_id":"drug-discovery-9780470942352","title":"Drug Discovery","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eSets forth the history, state of the science, and future directions of drug discovery\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eEdited by Jie Jack Li and Nobel laureate E. J. Corey, two leading pioneers in drug discovery and medicinal chemistry, this book synthesizes great moments in history, the current state of the science, and future directions of drug discovery into one expertly written and organized work. Exploring all major therapeutic areas, the book introduces readers to all facets and phases of drug discovery, including target selection, biological testing, drug metabolism, and computer-assisted drug design.\u003c\/p\u003e \u003cp\u003e\u003ci\u003eDrug Discovery\u003c\/i\u003e features chapters written by an international team of pharmaceutical and medicinal chemists. Contributions are based on a thorough review of the current literature as well as the authors'' firsthand laboratory experience in drug discovery. The book begins with the history of drug discovery, describing groundbreaking moments in the field. Next, it covers such topics as:\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTrade Review\u003c\/b\u003e\u003cbr\u003e\u003c\/p\u003e\u003cp\u003e“Taken together, the book is an excellent introduction into drug discovery and an eminent summary of the very important milestones of drug discovery in the most critical indication areas. This book is a valuable addition to the library of all different kinds of scientists working in the field of drug discovery.”  (\u003ci\u003eChemMedChem\u003c\/i\u003e, 1 October 2013)\u003c\/p\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003e\u003cb\u003eChapter 1. History of Drug Discovery 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 1\u003c\/p\u003e \u003cp\u003e2. Antibacterials 1\u003c\/p\u003e \u003cp\u003e3. Cancer Drugs 6\u003c\/p\u003e \u003cp\u003e4. Cardiovascular Drugs 10\u003c\/p\u003e \u003cp\u003e5. Cholesterol Drugs 16\u003c\/p\u003e \u003cp\u003e6. CNS Drugs 21\u003c\/p\u003e \u003cp\u003e7. Anti-inflammatory Drugs 26\u003c\/p\u003e \u003cp\u003e8. Anti-ulcer Drugs 30\u003c\/p\u003e \u003cp\u003e9. Antiviral Drugs 33\u003c\/p\u003e \u003cp\u003e10. References 38\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 2. Target Identification and Validation 43\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. History 43\u003c\/p\u003e \u003cp\u003e2. Definition of Drug Targets 43\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. Classification of Currently Utilized Drug Targets 45\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e4. Receptors as Drug Targets 46\u003c\/p\u003e \u003cp\u003e5. Enzymes as Drug Targets 48\u003c\/p\u003e \u003cp\u003e6. Transporter Proteins as Drug Targets 49\u003c\/p\u003e \u003cp\u003e7. Modern Technologies Employed in Target Identification and Validation 49\u003c\/p\u003e \u003cp\u003e8. Impact of Therapeutic Modalities on the Selection Drug Targets 62\u003c\/p\u003e \u003cp\u003e9. Future Directions 63\u003c\/p\u003e \u003cp\u003e10. References\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3. \u003ci\u003eIn vitro and in vivo \u003c\/i\u003eAssays 67\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 67\u003c\/p\u003e \u003cp\u003e2. The Testing Funnel 67\u003c\/p\u003e \u003cp\u003e3. In vitro assays 70\u003c\/p\u003e \u003cp\u003e4. In vivo Assays 89\u003c\/p\u003e \u003cp\u003e5. Outlook 92\u003c\/p\u003e \u003cp\u003e6. References 93\u003c\/p\u003e \u003cp\u003eChapter 4. Drug Metabolism and Pharmacokinetics in Drug Discovery 95\u003c\/p\u003e \u003cp\u003e1. Introduction 95\u003c\/p\u003e \u003cp\u003e2. Drug Metabolism 97\u003c\/p\u003e \u003cp\u003e3. Pharmacokinetic Fundamentals 106\u003c\/p\u003e \u003cp\u003e4. Drug Metabolism and Pharmacokinetics in Drug Discovery 95\u003c\/p\u003e \u003cp\u003e1. Introduction 95\u003c\/p\u003e \u003cp\u003e2. Drug Metabolism 97\u003c\/p\u003e \u003cp\u003e3. Pharmacokinetic Fundamentals 106\u003c\/p\u003e \u003cp\u003e4. Pharmacokinetics Studies in Support of Drug Optimization 112\u003c\/p\u003e \u003cp\u003e5. Absorption and Permeability 114\u003c\/p\u003e \u003cp\u003e6. Drug Transporters 117\u003c\/p\u003e \u003cp\u003e7. Protein Binding 119\u003c\/p\u003e \u003cp\u003e8. Pharmacokinetics and Pharmacodynamics 123\u003c\/p\u003e \u003cp\u003e9. Predicting Human Pharmacokinetics 130\u003c\/p\u003e \u003cp\u003e10. Summary 133\u003c\/p\u003e \u003cp\u003e11. References 133\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 5. Cardiovascular Drugs 137\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 137\u003c\/p\u003e \u003cp\u003e2. Early History of Coronary Heart Disease (CHD) 138\u003c\/p\u003e \u003cp\u003e3. Lipid Lowering Agents 139\u003c\/p\u003e \u003cp\u003e4. Antihypertensive Agents 153\u003c\/p\u003e \u003cp\u003e5. Antithrombotic Drugs 177\u003c\/p\u003e \u003cp\u003e6. Thrombolytic Agents 190\u003c\/p\u003e \u003cp\u003e7. Anti-anginal Agents 191\u003c\/p\u003e \u003cp\u003e8. Heart Failure Drugs 191\u003c\/p\u003e \u003cp\u003e9. The Future 193\u003c\/p\u003e \u003cp\u003e10. References 193\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 6. Diabetes Drugs 201\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 201\u003c\/p\u003e \u003cp\u003e2. Current therapies for Type 2 Diabetes 204\u003c\/p\u003e \u003cp\u003e3. Other Treatments for T2DM 215\u003c\/p\u003e \u003cp\u003e4. Novel Mechanisms of Action: Future Treatments for Type 2 Diabetes 217\u003c\/p\u003e \u003cp\u003e5. Current Therapies for Type 1 Diabetes 221\u003c\/p\u003e \u003cp\u003e6. Future Treatments for Type 1 Diabetes 227\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7. Future Prospects for New Diabetes Drugs 231\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e8. References 231\u003c\/p\u003e \u003cp\u003eChapter 7. CNS Drugs 241\u003c\/p\u003e \u003cp\u003e1. Introduction 241\u003c\/p\u003e \u003cp\u003e2. Antipsychotic Drugs 241\u003c\/p\u003e \u003cp\u003e3. Antidepressant drugs 246\u003c\/p\u003e \u003cp\u003e4. Drugs for Epilepsy and Bipolar Disorder 255\u003c\/p\u003e \u003cp\u003e5. Anxiolytic Drugs 259\u003c\/p\u003e \u003cp\u003e6. Centrally Acting Analgesic Drugs 262\u003c\/p\u003e \u003cp\u003e7. Drugs for treating Substance Abuse and ADHD 265\u003c\/p\u003e \u003cp\u003e8. Drugs for Neurodegenerative Diseases 267\u003c\/p\u003e \u003cp\u003e9. Future Prospects for New CNS Drugs 273\u003c\/p\u003e \u003cp\u003e10. References 276\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 8. Cancer Drugs 283\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 283\u003c\/p\u003e \u003cp\u003e2. Historical Perspective of Cancer Drugs 285\u003c\/p\u003e \u003cp\u003e3. Antimetabolites 286\u003c\/p\u003e \u003cp\u003e4. Alkylating Agents 291\u003c\/p\u003e \u003cp\u003e5. Platinum Complexes 294\u003c\/p\u003e \u003cp\u003e6. Plant and Marine Based Natural Products 295\u003c\/p\u003e \u003cp\u003e7. Toposiomerase Inhibitors 300\u003c\/p\u003e \u003cp\u003e8. Antitumor Antibiotics 305\u003c\/p\u003e \u003cp\u003e9. Tyrosine Kinase Inhibitors (TKI) 306\u003c\/p\u003e \u003cp\u003e10. Hormones 314\u003c\/p\u003e \u003cp\u003e11. Histone Deacylase (HDAC) Inhibitors 321\u003c\/p\u003e \u003cp\u003e12. Miscellaneous Cancer Drugs 323\u003c\/p\u003e \u003cp\u003e13. Conclusion 325\u003c\/p\u003e \u003cp\u003e14. References 326\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 9. Antiinflammatory and Immunomodulatory Drugs 333\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 333\u003c\/p\u003e \u003cp\u003e2. Arachidonic Acid Cascade 334\u003c\/p\u003e \u003cp\u003e3. Leukotriene Pathway Inhibitors 347\u003c\/p\u003e \u003cp\u003e4. Anti-histamines 351\u003c\/p\u003e \u003cp\u003e5. Corticosteroids 353\u003c\/p\u003e \u003cp\u003e6. Rheumatoid Arthritis 356\u003c\/p\u003e \u003cp\u003e7. Osteoarthritis 363\u003c\/p\u003e \u003cp\u003e8. Chronic Inflammatory Arthritis and Gout 364\u003c\/p\u003e \u003cp\u003e9. Multiple Sclerosis 366\u003c\/p\u003e \u003cp\u003e10. Transplantation 368\u003c\/p\u003e \u003cp\u003e11. Biological Agents That Suppress Cytokine Production or Signaling 372\u003c\/p\u003e \u003cp\u003e12. B Cell Therapy 374\u003c\/p\u003e \u003cp\u003e13. Cytotoxic T-lymphocyte Antigen 4 (CTLA4) 374\u003c\/p\u003e \u003cp\u003e14. Interleukins 375\u003c\/p\u003e \u003cp\u003e15. Safety 377\u003c\/p\u003e \u003cp\u003e16. Summary 377\u003c\/p\u003e \u003cp\u003e17. References 378\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 10. Anti-bacterial Drugs 385\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 385\u003c\/p\u003e \u003cp\u003e2. The Rise and Decline of Antibiotics 386\u003c\/p\u003e \u003cp\u003e3. The Unique Challenges of Anti-bacterial Drug Discovery 387\u003c\/p\u003e \u003cp\u003e4. Antibiotic Classes 390\u003c\/p\u003e \u003cp\u003e5. Emerging Strategies to Discover New Anti-bacterial Drugs 420\u003c\/p\u003e \u003cp\u003e6. Conclusions 425\u003c\/p\u003e \u003cp\u003e7. References 425\u003c\/p\u003e \u003cp\u003e\u003cb\u003eChapter 11. Antiviral Drug Discovery 437\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. Introduction 437\u003c\/p\u003e \u003cp\u003e2. Human Immunodeficiency Virus-1 Inhibitors 442\u003c\/p\u003e \u003cp\u003e3. Hepatitis B Virus Inhibitors 459\u003c\/p\u003e \u003cp\u003e4. Hepatitis C Virus Inhibitors 463\u003c\/p\u003e \u003cp\u003e5. Inhibitors of Respiratory Viruses-Influenza and Respiratory Syncytial Virus 476\u003c\/p\u003e \u003cp\u003e6. Herpesviridae Inhibitors 487\u003c\/p\u003e \u003cp\u003e7. Epilogue 490\u003c\/p\u003e \u003cp\u003e8. References 490\u003c\/p\u003e \u003cp\u003eIndex 517\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":49402461585751,"sku":"9780470942352","price":99.86,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9780470942352.jpg?v=1730480480","url":"https:\/\/bookcurl.com\/products\/drug-discovery-9780470942352","provider":"Book Curl","version":"1.0","type":"link"}